About LyGenesis
LyGenesis is a company based in Pittsburgh (United States) founded in 2017 by Paulo Fontes and Michael Hufford. LyGenesis has raised $27.85 million across 4 funding rounds from investors including Juvenescence, Prime Movers Lab and Longevity Vision Holding. LyGenesis offers products and services including LIV-001, Thymus Therapy, Kidney Therapy, and Pancreas Therapy. LyGenesis operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Terns Pharmaceutical, among others.
- Headquarter Pittsburgh, United States
- Founders Paulo Fontes, Michael Hufford
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lygenesis, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$27.85 M (USD)
in 4 rounds
-
Latest Funding Round
$19 M (USD), Series A
Oct 05, 2023
-
Investors
Juvenescence
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of LyGenesis
LyGenesis offers a comprehensive portfolio of products and services, including LIV-001, Thymus Therapy, Kidney Therapy, and Pancreas Therapy.
Therapy for end-stage liver disease using lymph nodes.
Treatment for thymus-related aging and immune function.
Therapy for end-stage renal disease via organ regeneration.
Cell therapy for Type 1 diabetes management.
People of LyGenesis
Unlock access to complete
Co Team
1 people
Operations Team
1 people
Leadership Team
1 people
CSO Team
1 people
Product Management Team
1 people
Unlock access to complete
Funding Insights of LyGenesis
LyGenesis has successfully raised a total of $27.85M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $19 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in LyGenesis
LyGenesis has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Juvenescence, Prime Movers Lab and Longevity Vision Holding.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Support is provided for longevity breakthrough initiatives by Longevity Vision Holding.
|
Locked | Locked | Locked | |
|
Venture capital firm funding breakthrough scientific startups and innovative sectors worldwide.
|
Locked | Locked | Locked | |
|
Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health
|
Locked | Locked | Locked |
Investor details for LyGenesis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by LyGenesis
Investment portfolio details for LyGenesis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - LyGenesis
Detailed financials for LyGenesis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lygenesis Comparisons
Peer comparison for LyGenesis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of LyGenesis
LyGenesis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Terns Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Therapies for liver disease and cancer are developed.
|
|
| Locked | Locked | Locked |
Therapeutics are developed for diseases with impaired kidney function.
|
Detailed competitors of LyGenesis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lygenesis
Complete news archive for LyGenesis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LyGenesis
LyGenesis was founded in 2017 and raised its 1st funding round 1 year after it was founded.
LyGenesis is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
LyGenesis is a funded company, having raised a total of $27.85M across 4 funding rounds to date.
LyGenesis was founded in 2017 in Pittsburgh, United States, within the biotechnology sector focused on regenerative medicine. Organ regeneration technology is being developed by the company, utilizing patients own lymph nodes to regrow damaged organs. Preclinical studies have been completed for the lead program targeting end-stage liver disease, with operations centered on advancing treatments for liver disorders.
LyGenesis's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
LyGenesis offers LIV-001, Thymus Therapy, Kidney Therapy, and Pancreas Therapy.
LyGenesis has 3 investors. Key investors include Juvenescence, Prime Movers Lab, and Longevity Vision Holding.